Tenofovir nephrotoxicity: Acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities

Kidney International

Volumn 78, Issue 11, 2010, Pages 1171-1177

  Herlitz, Leal C ^a   Mohan, Sumit ^a   Stokes, Michael B ^a   Radhakrishnan, Jai ^a   D'Agati, Vivette D ^a   Markowitz, Glen S ^a  

^a VC14 238 ^*  (United States)

Author keywords

acute kidney injury; drug nephrotoxicity; HIV; mitochondria; renal pathology

Indexed keywords

CREATININE; TENOFOVIR;

ACUTE KIDNEY TUBULE NECROSIS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; GLUCOSURIA; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KIDNEY FAILURE; KIDNEY INJURY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEINURIA;

EID: 78349304725     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.318     Document Type: Article

References (20)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. US Department of Health and Human Services, Rockville, MD. 1 December 2009. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf, accessed in 5 April 2010.
2. Jimenez-Nacher I, Garcia B, Barreiro P et al. Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. J Antimicrob Chemother 2008; 62: 186-822.
3. Tanji N, Tanji K, Kambham N et al. Adefovir Nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol 2001; 32: 734-740.
4. Meier P, Dautheville-Guibal S, Ronco P et al. Cidofovir-induced end-stage renal failure. Nephrol Dial Transplant 2002; 17: 148-149.
5. Gilead Sciences. Viread (Tenofovir Disoproxill Fumarate): Highlights of Prescribing Information. Gilead Sciences: Foster City, CA, 2010. www.viread.com, accessed in March 2010.
6. Nelson M, Katlama C, Montaner J et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007; 21: 1273-1281.
7. Labarga P, Barreiro P, Matin-Carbonero L et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009; 23: 689-696.
8. Verhelst D, Monge M, Meynard JL et al. Fanconi syndrome and renal failure induced by Tenofovir: a first case report. Am J Kid Dis 2002; 40: 1331-1333.
9. Coca S, Perazella M. Acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 2002; 324: 342-344.
10. Rifkin B, Perazella M. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med 2004; 117: 282-283.
11. Peyriere H, Reynes J, Rouanet I et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Aquir Immune Defic Syndr 2004; 35: 269-273.
12. Zimmerman A, Pizzoferrato T, Bedford J et al. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006; 42: 283-290.
13. Agarwala R, Mohan S, Herlitz L et al. 41-year-old HIV patient with proteinuria and progressive renal dysfunction. Kidney Int 2010; 77: 475-476.
14. Cote H, Magil A, Harris M et al. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. Antivir Ther 2006; 11: 79-86.
15. Brinkman K, ter Hofstede H, Burger D et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as a common pathway. AIDS 1998; 12: 1735-1744.
16. Lebrecht D, Venhoff A, Kirschner J et al. Mitochondrial tubulopathy in tenofovir disoproxil fumarate-treated rats. J Acquir Immune Defic Syndr 2009; 51: 258-263.
17. Kohler J, Hosseini S, Hoying-Brandt A et al. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest 2009; 89: 513-519.
18. Gupta S, Eustace J, Winston J et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40: 1559-1585.
19. Rodriguez-Novoa S, Labarga P, Soriano V et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 2009; 48: e108-e116.
20. Izzedine H, Harris M, Perazella M. The nephrotoxic effects of HAART. Nat Rev Nephrol 2009; 5: 563-573.